These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 30319641

  • 1. Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling.
    Mike EV, Makinde HM, Der E, Stock A, Gulinello M, Gadhvi GT, Winter DR, Cuda CM, Putterman C.
    Front Immunol; 2018; 9():2189. PubMed ID: 30319641
    [Abstract] [Full Text] [Related]

  • 2. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway.
    Wen J, Xia Y, Stock A, Michaelson JS, Burkly LC, Gulinello M, Putterman C.
    J Autoimmun; 2013 Jun; 43():44-54. PubMed ID: 23578591
    [Abstract] [Full Text] [Related]

  • 3. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.
    Chalmers SA, Wen J, Shum J, Doerner J, Herlitz L, Putterman C.
    Clin Immunol; 2017 Dec; 185():100-108. PubMed ID: 27570219
    [Abstract] [Full Text] [Related]

  • 4. FTY720 attenuates behavioral deficits in a murine model of systemic lupus erythematosus.
    Shi D, Tian T, Yao S, Cao K, Zhu X, Zhang M, Wen S, Li L, Shi M, Zhou H.
    Brain Behav Immun; 2018 May; 70():293-304. PubMed ID: 29548997
    [Abstract] [Full Text] [Related]

  • 5. Sphingosine 1-phosphate signaling at the blood-brain barrier.
    Prager B, Spampinato SF, Ransohoff RM.
    Trends Mol Med; 2015 Jun; 21(6):354-63. PubMed ID: 25939882
    [Abstract] [Full Text] [Related]

  • 6. B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus.
    Wen J, Doerner J, Chalmers S, Stock A, Wang H, Gullinello M, Shlomchik MJ, Putterman C.
    J Neuroinflammation; 2016 Apr 07; 13(1):73. PubMed ID: 27055816
    [Abstract] [Full Text] [Related]

  • 7. The T Cell Receptor Repertoire in Neuropsychiatric Systemic Lupus Erythematosus.
    Moore E, Huang MW, Jain S, Chalmers SA, Macian F, Putterman C.
    Front Immunol; 2020 Apr 07; 11():1476. PubMed ID: 32765512
    [Abstract] [Full Text] [Related]

  • 8. Treatment with lysophosphatidic acid prevents microglial activation and depression-like behaviours in a murine model of neuropsychiatric systemic lupus erythematosus.
    Nagata W, Koizumi A, Nakagawa K, Takahashi S, Gotoh M, Satoh Y, Ishizuka T.
    Clin Exp Immunol; 2023 Apr 25; 212(2):81-92. PubMed ID: 36718978
    [Abstract] [Full Text] [Related]

  • 9. Constitutive knockout of interleukin-6 ameliorates memory deficits and entorhinal astrocytosis in the MRL/lpr mouse model of neuropsychiatric lupus.
    Reynolds J, Huang M, Li Y, Meineck M, Moeckel T, Weinmann-Menke J, Mohan C, Schwarting A, Putterman C.
    J Neuroinflammation; 2024 Apr 10; 21(1):89. PubMed ID: 38600510
    [Abstract] [Full Text] [Related]

  • 10. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
    Spampinato SF, Obermeier B, Cotleur A, Love A, Takeshita Y, Sano Y, Kanda T, Ransohoff RM.
    PLoS One; 2015 Apr 10; 10(7):e0133392. PubMed ID: 26197437
    [Abstract] [Full Text] [Related]

  • 11. CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice.
    Huang MW, Stock AD, Putterman C.
    Front Immunol; 2021 Apr 10; 12():763065. PubMed ID: 34868008
    [Abstract] [Full Text] [Related]

  • 12. TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice.
    Wen J, Doerner J, Weidenheim K, Xia Y, Stock A, Michaelson JS, Baruch K, Deczkowska A, Gulinello M, Schwartz M, Burkly LC, Putterman C.
    J Autoimmun; 2015 Jun 10; 60():40-50. PubMed ID: 25911200
    [Abstract] [Full Text] [Related]

  • 13. Lipocalin-2 drives neuropsychiatric and cutaneous disease in MRL/lpr mice.
    Garcia SJ, Mike EV, Zhang J, Cuda CM, Putterman C.
    Front Immunol; 2024 Jun 10; 15():1466868. PubMed ID: 39399497
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fingolimod protects against neonatal white matter damage and long-term cognitive deficits caused by hyperoxia.
    Serdar M, Herz J, Kempe K, Lumpe K, Reinboth BS, Sizonenko SV, Hou X, Herrmann R, Hadamitzky M, Heumann R, Hansen W, Sifringer M, van de Looij Y, Felderhoff-Müser U, Bendix I.
    Brain Behav Immun; 2016 Feb 10; 52():106-119. PubMed ID: 26456693
    [Abstract] [Full Text] [Related]

  • 17. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
    Chalmers SA, Wen J, Doerner J, Stock A, Cuda CM, Makinde HM, Perlman H, Bosanac T, Webb D, Nabozny G, Fine JS, Klein E, Ramanujam M, Putterman C.
    Arthritis Res Ther; 2018 Jan 25; 20(1):10. PubMed ID: 29370834
    [Abstract] [Full Text] [Related]

  • 18. Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke.
    Salas-Perdomo A, Miró-Mur F, Gallizioli M, Brait VH, Justicia C, Meissner A, Urra X, Chamorro A, Planas AM.
    Sci Rep; 2019 Jun 05; 9(1):8309. PubMed ID: 31165772
    [Abstract] [Full Text] [Related]

  • 19. Modulating sphingosine 1-phosphate signaling with DOP or FTY720 alleviates vascular and immune defects in mouse sepsis.
    Hemdan NY, Weigel C, Reimann CM, Gräler MH.
    Eur J Immunol; 2016 Dec 05; 46(12):2767-2777. PubMed ID: 27683081
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.